Men treated with androgen deprivation therapy (ADT) for prostate cancer were more likely to demonstrate impaired cognitive performance within 6 months and for up to 12 months after initiation of ADT, a new study published online early in the Journal of Clinical Oncology has shown.
For the study, researchers at Moffitt Cancer Center in Tampa, Florida, sought to determine the effect of ADT on cognitive performance identify predictors of impaired performance. Researchers enrolled 58 patients with prostate cancer whom they assessed before or within 21 days of starting ADT and 6 and 12 months afterwards.
Participants were compared with matched controls with prostate cancer treated with prostatectomy as well as men with without prostate cancer.
Results showed that participants that received ADT had higher rates of impaired cognitive performance over time compared with all controls.
Researchers found that those who received ADT were more likely to exhibit impaired performance within 6 and 12 months versus the other two groups despite no differences in baseline characteristics.
Exploratory genetic analyses showed that GNB3 single-nucleotide polymorphism rs1047776 was associated with higher rates of impaired cognitive performance over time in patients treated with ADT.
The findings may result in changes to patient education regarding the benefits and risks of ADT.
Men receiving androgen-deprivation therapy (ADT) for prostate cancer may be at risk for cognitive impairment; however, evidence is mixed in the existing literature.